SILENCE DISEASE. AMPLIFY LIFE.
Alnylam Pharmaceuticals is the pioneer and global leader in RNA interference (RNAi) therapeutics, having discovered the mechanism and translated it into six FDA-approved medicines since 2018. The company develops small interfering RNA (siRNA) drugs that silence disease-causing genes at their source, targeting rare diseases, cardiovascular disease, and neurological conditions. Headquartered in Cambridge, Massachusetts, Alnylam employs 2,500+ people and operates globally across six continents.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountApr 2020
Oct 2004
Jan 2003
Aug 2002
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...
Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...
